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To evaluate the effectiveness of human papillomavirus (HPV) testing in primary cervical screening. This was a cross-sectional study
from the recruitment phase of a prospective randomised trial. Women were screened for HPV in addition to routine cervical
cytology testing. Greater Manchester, attendees at routine NHS Cervical Screening Programme. In all, 24 510 women aged 20–64
screened with liquid-based cytology (LBC) and HPV testing at entry. HPV testing in primary cervical screening. Type-specific HPV
prevalence rates are presented in relation to age as well as cytological and histological findings at entry. In all, 24 510 women had
adequate cytology and HPV results. Cytology results at entry were: 87% normal, 11% borderline or mild, 1.1% moderate and 0.6%
severe dyskaryosis or worse. Prevalence of HPV decreased sharply with age, from 40% at age 20–24 to 12% at 35–39 and 7% or less
above age 50. It increased with cytological grade, from 10% of normal cytology and 31% of borderline to 70% mild, 86% moderate,
and 96% of severe dyskaryosis or worse. HPV 16 or HPV 18 accounted for 64% of infections in women with severe or worse
cytology, and one or both were found in 61% of women with severe dyskaryosis but in only 2.2% of those with normal cytology. The
majority of young women in Greater Manchester have been infected with a high-risk HPV by the age of 30. HPV testing is practicable
as a primary routine screening test, but in women aged under 30 years, this would lead to a substantial increase in retesting and
referral rates. HPV 16 and HPV 18 are more predictive of underlying disease, but other HPV types account for 30% of high-grade
disease.
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Cervical cancer is the second most common cancer among women
worldwide, and ranks first in many developing countries (Parkin,
2004). Human papillomaviruses (HPV), most frequently HPV 16,
are the primary cause of cervical carcinogenesis (IARC, 1995).
Over 100 HPV types have now been described, including about 20
‘high-risk’ types that are associated with cervical cancer (Clifford
et al, 2005). The overall prevalence of HPV in cervical cancers in a
large international study was over 99%, implying the highest
attributable fraction ever identified for a specific cause of a major
human cancer (Walboomers et al, 1999). In many developed
countries, particularly the UK, systematic cervical screening based
on cytology has been responsible for a significant fall in the
incidence and death rate from cervical cancer (Peto et al, 2004).
The NHS Cervical Screening Programme in England now offers
screening 3 yearly between ages 25 and 49 and 5 yearly between 50
and 64 years, and liquid-based cytology (LBC) is currently being
implemented. Nonrandomised studies have shown that HPV DNA
testing is more sensitive than cytology for detecting CIN, and the
International Agency for Research on Cancer (IARC) recently
concluded that testing for HPV as a primary screening modality
could reduce cancer incidence and mortality (IARC, 2004).
In order to evaluate the effectiveness of HPV testing in primary
cervical screening, the Trial, A Randomised Trial in Screening to
Improve Cytology (ARTISTIC) Trial is being conducted within the
routine NHS Cervical Screening Programme in Greater Manche-
ster. This randomised trial will compare outcomes in women
whose HPV test result is concealed with those in whom it is
revealed and acted upon. In this paper, we report prevalence rates
of HPV 16, HPV 18 and other high-risk HPVs in relation to age,
cytology and histology at entry to the trial.
METHODS
Between July 2001 and October 2003, women aged 20– 64 years
attending for routine cervical screening in four health authorities
in the Manchester area (Manchester, Salford & Trafford, Stockport
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and Wigan & Leigh) were invited to participate. The trial, which
was approved by the North West Multicentre Research Ethics
Committee, was explained in a letter enclosed with the invitation to
attend for a routine smear. Women willing to participate were
asked to sign informed consent before having a smear collected for
LBC and HPV testing. This is a population-based study and is
therefore representative of women in Greater Manchester, a
heavily populated British conurbation.
The cervical sample was collected using the broom-like device of
the Thin-Prept (Cytyc) kit and rinsed into a vial containing
PreservCyts transport medium. The sample and consent form
were sent to the Manchester Cytology Centre laboratory in
Manchester Royal Infirmary if they were collected in Manchester,
Salford & Trafford, or Wigan & Leigh, and to Stepping Hill
Hospital cytology laboratory if they were from the Stockport area.
Samples accompanied by a consent form were flagged on receipt
on the laboratory database. Consent forms were checked and
forwarded to the ARTISTIC trial office, which sent a letter
notifying participants of their random allocation (HPV result
revealed or concealed).
Design of the trial
The data reported in this study are derived from the cytology and
HPV testing performed during the recruitment phase. Figure 1
shows the design of the trial which will be completed in 2006/7.
Women were randomised in a 3 : 1 ratio to the revealed arm or the
concealed arm. In both arms the cervical sample was processed for
cytology and then sent to the virology laboratory. HPV testing and
cytology were thus conducted independently. Women with
inadequate cytology at first visit were resampled. All women are
being recalled for a second round of screening by LBC and HPV
testing at 36 months.
Concealed arm
All HPV results at entry and subsequently are concealed from the
women and from clinical staff including the HPV results at 36
months. All women in the concealed arm, and those in the revealed
arm who remained HPV-negative, were referred to colposcopy
according to national guidelines at that time, that is (i) after three
consecutive inadequate samples; (ii) after three consecutive
borderline smears; (iii) after an initial borderline or mildly
dyskaryotic smear followed by another showing mild dyskaryosis
or worse; or (iv) following a single smear showing moderate
dyskaryosis or worse.
Revealed arm
Women in the revealed arm with normal cytology at entry who
tested HPV positive were invited for a second HPV test 12 months
after entry. If this second test was also positive, they were invited
to choose between immediate colposcopy or a repeat HPV test
after a further 12 months. If this third test was again positive,
women were referred to colposcopy.
Intervention group: HPV results revealed
1st smear/HPV test
Control group/HPV result concealed
1st smear/HPV test
Normal Mild/bord Moderate Normal Mild/bord
HPV
neg
HPV
pos
2nd smear/HPV test
Bord* Mild
3rd smear/HPV test
Normal
Normal and
HPV neg
Abnormal or
HPV pos
Colposcopy Colposcopy
2nd smear/HPV test
Mild
3rd smear/HPV test
Normal Bord*
Normal Abnormal
Randomisation 3:1
Baseline
12
months
6
months
HPV
neg
HPV
pos
2nd HPV test
HPV
neg
HPV
pos
24
months
3rd HPV test or
colposcopy
HPV
neg
HPV
pos
Colposcopy
Colposcopy
ColposcopyColposcopy
Colposcopy
Smear/HPV at 36 months
Moderate
* Referral to colposcopy vary depending on cytology history, some women could be referred to colposcopy only after three consecutive borderline smears or after a mild followed by
  a borderline smear. 
 

Figure 1 ARTISTIC Trial protocol for the management of women with normal and abnormal cytology and HPV-positive and -negative tests, in the
revealed arm.
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Outcome measures
Primary outcome measures will include the proportion of
additional CIN3 lesions diagnosed in the revealed arm in
cytologically normal women who were HPV positive at entry and
any resulting reduction in their CIN3 detection rate at the 3 year
second screening round (CIN3 cases diagnosed in women who are
cytologically normal at 3 years will be ignored in this concealed/
revealed comparison). Other relevant outcomes are (a) the
sensitivity and specificity of persistently detectable HPV for
diagnosis of CIN3 or cancer; (b) the cost effectiveness of HPV
testing; (c) the psychological effects of HPV testing; (d) attendance
rates among HPV positive women when recalled after 1 year for
retesting and (e) their preference between immediate colposcopy
and further HPV testing if they are still HPV positive. Some HPV
positive women fail to return for a second HPV test after 12
months, and the trial will also provide substantial evidence on the
effects of retesting HPV positive women after 3 years, which may
prove as sensitive but more specific for CIN3 diagnosis compared
with retesting after 1 year.
Laboratory procedures
LBC using ThinPreps ThinPreps vials were collected from the
participating practices or clinics and sent either to Manchester
Cytology Centre or to Stepping Hill Hospital Cytology Laboratory.
Vials not accompanied by a consent form were not processed until
the consent form was received at the laboratory. Laboratory
numbers were allocated to the samples before automatic staining
and routine processing in cytology.
Most were processed using the multi sample ThinPreps 3000
processor (Cytyc). The single sample ThinPreps 2000 (Cytyc) was
used if an extra slide needed to be made from a sample because the
initial slide appeared unsatisfactory or if only a few samples
needed to be processed.
Vials containing the residual sample were sent to the Virology
Laboratory in Manchester Royal Infirmary for HPV testing by the
Digene Hybrid Captures 2 (hc2) assay. Laboratory numbers were
allocated to the samples before automatic staining and routine
processing. Procedures are in place to ensure that cross
contamination by HPV does not occur in the T3000 processor
and swabs are taken to ensure no contamination is present.
HPV testing using Hybrid Captures 2 (hc2)
Detection of high-risk HPV genotypes by hc2 assay Cervical
samples collected into Cytyc LBC medium were tested for high-risk
HPV DNA by hc2 according to the manufacturer’s instructions.
Briefly, after treatment with conversion buffer, single-stranded
DNA (ssDNA) was produced by adding denaturing fluid and
heating at 651C for 45 min. Following hybridisation of ssDNA to
high-risk HPV specific RNA probes the DNA/RNA hybrids were
captured onto anti-DNA/RNA antibody coated micro-titre plates
prior to detection of the hybrids using an alkaline phosphatase
conjugated anti-DNA/RNA antibody in conjunction with a light
emitting substrate. Positive results were expressed in relative light
units (RLUs) compared with a positive control containing
1 pg ml1 of HPV DNA. The high-risk HPV types detected by the
assay are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. We
classified samples as HPV positive according to the manufacturer’s
instructions at the outset of the study, which was to use a positive
cut off as 1 RLU/control.
HPV genotyping (Roche reverse line blot assay)
Genotyping of hc2 positive samples was carried out using the
prototype reverse line blot assay supplied by Roche.
DNA was extracted from 50 ml of the pelleted sample stored at
701C using the automated Roche MagNAPure LC system.
Extracted DNA was amplified using the PGMY primer reagents
provided by Roche. Biotinylated PCR product was then denatured
and captured onto nylon strips coated with HPV type specific
oligonucleotides. Immobilised product was visualised using
streptavidin-horseradish peroxidase-mediated colour precipita-
tion.
Data management
Trial participants were flagged on the routine cytology and
histology records of both cytology laboratories. In order to avoid
the possibility that any histology results have been obtained from
the second screening round, we have censored histology records at
2 years. Name, address and date of birth are routinely used by
cytology laboratories to match new smears against a woman’s
previous screening record. A separate database was maintained by
the virology laboratory. Relevant results were sent to the trial office
in Manchester regularly, where they were matched and appended
to participants’ records on an Access 2000 database. Stata version 8
statistical software (StataCorp., 2004) was used for all analyses.
RESULTS
A total of 25 020 women were enrolled of whom 397 (1.6%) had an
inadequate first smear at entry including 71 (0.3%) who did not
provide an adequate repeat smear. These 71 women were referred
for colposcopy according to national guidelines and excluded from
further analysis. The cytology results presented thus correspond to
the first adequate smear. In all, 85 women had a conventional
smear and no HPV test at entry, 137 had samples that were
insufficient for HPV testing, 84 were younger than 20 and 133 were
older than 64 years of age. There were thus 24 510 (18 386 revealed
and 6124 concealed) eligible women with satisfactory cytology and
HPV results at entry.
Cytology and HPV results
Table 1 shows that cytology and HPV results at entry did not differ
between the randomised arms and are therefore presented
together; 87% of women had normal cytology, 11% had borderline
smears or mild dyskaryosis, 1.1% had moderate dyskaryosis, and
0.8% had severe dyskaryosis or worse abnormality. The mean age
was 40.2 years in both arms. The prevalence of high-risk HPV
detection (Figure 2) declined from 40% in women aged 20– 24 to
12% at 35–39 and 6% at 55 years or older.
Figure 3 shows the prevalence of HPV infection by age and
cytology at entry. HPV prevalence increased with the level of
cytological abnormality, proportionally more so at older ages. HPV
prevalence rates at age 20–29 years were 55% (borderline), 87%
Table 1 Cytology and high-risk HPV results by randomisation arms at
entry
Revealed arm Concealed arm
Cytology HPV  HPV + Total HPV  HPV + Total
Negative 14 367 1675 16 042 (87.3%) 4787 551 5338 (87.2%)
Borderline 923 420 1343 (7.3%) 309 137 446 (7.3%)
Mild 196 447 643 (3.5%) 69 166 235 (3.8%)
Moderate 34 170 204 (1.1%) 4 63 67 (1.1%)
Severe/worse 6 148 154 (0.8%) 2 36 38 (0.6%)
Total 15 526 2860 18 386 (100%) 5171 953 6124 (100%)
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(mild), 92% (moderate) and 99% (severe). By age 50–64 years
these rates had fallen to 10% (borderline), 28% (mild), 56%
(moderate) and 89% (severe).
Table 2 shows the prevalence of abnormal cytology by age and
HPV detection. The overall proportion of women with high-grade
(moderate or severe) cytology declined from 4.2% (215/5166) at
age 20– 29 to 1.6% (223/13,731) at age 30– 49. This marked
reduction in high-grade disease appears to be due entirely to the
much lower overall HPV prevalence in women aged 30 –49 years,
as the prevalence of high-grade abnormality in HPV-positive
women was identical at age 20– 29 years (11.6%: 203/1749) and at
age 30–49 (11.6%: 197/1697). Above age 50, however, high-grade
cytological abnormality was diagnosed in only 4.6% (17/367) of
HPV-positive women and in 0.4% overall. The number of women
who would have been referred for follow-up if primary screening
with HPV testing replaced cytology can also be seen in Table 2. The
proportion of smears that were abnormal was 22% (1153/5166) at
aged 20–29 years, 12% (1640/13731) at age 30– 49 years and 6.0%
(338/5613) at age 50–64 years. The proportions HPV positive were
34% at 20–29 years, 12% at 30–49 years and 6.5% at 50–64 years.
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Figure 2 Prevalence of high-risk HPV (HR HPV) by Hybrid Capture 2 (HC2) according to age quinquennia.
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Figure 3 Prevalence of high-risk HPV (HR HPV) by Hybrid Capture 2 (HC2) by cytology grade within different age bands.
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Table 3 shows the proportions of women who tested positive for
HPV 16, positive for HPV 18 (but not 16) and positive for hc2 in
the absence of HPV 16 or HPV 18, in relation to age, cytology and
histology at entry. The overall prevalence was 3.3% for HPV 16 and
1.1% for HPV 18. Among women with any high-risk type detected
by hc2, the proportion who had HPV 16 was 31% at age 20– 24
years, 23% at 25–34 years and 12% at 35–64 years. As the grade of
cytological abnormality increased the proportion of women with
HPV 16 infections increased from 1.5% in women with normal
cytology to over 50% in those with severe dyskaryosis.
The lower part of Table 3 shows histological findings (worst
histology within 2 years) among 1061 women with abnormal
cytology at entry for whom a biopsy was obtained. No histology is
yet available for the remaining 2069 women with an abnormal
entry smear (bottom line, Table 3: abnormal cytology resolved
or still being followed-up cytologically). Among women with
histology, CIN3, CGIN or cancer was diagnosed in 46%, (150/325)
of women with HPV 16, 28% (20/72) of those with HPV 18 (not
16), 20% (81/411) of those with other HPVs, and in only 3%
(8/253) of those whose entry smears were hc2 negative. The hc2
test was positive in 92% of women with CIN2 and 97% with CIN3,
CGIN or cancer. HPV 16 was detected in 59% of women with CIN3
or squamous cell carcinoma. HPV 18 was detected in 38% of
women with CGIN or adenocarcinoma but in only 6% with CIN3
or squamous cell carcinoma.
DISCUSSION
The ARTISTIC trial cohort represents the largest population of
women in the UK to have undergone routine cervical screening
with both LBC and HPV testing. The study population spanned the
20–64 age range of screened women when the trial opened,
although the lower age threshold for routine cervical screening in
England has since been increased from 20 to 25 years.
Our age-specific HPV positive rates in different grades of
cytological abnormality were similar to those in the HART study
in which over 10 000 women were screened with conventional
Table 2 Cytological abnormality by age and high-risk HPV detection
Age Normal Borderline Mild Moderate Severe Total
20–29
HPV+ 51.2% (895) 16.5% (289) 20.7% (362) 7.0% (122) 4.6% (81) 100% (1749)
HPV 91.3% (3119) 6.8% (233) 1.5% (53) 0.32% (11) 0.03% (1) 100% (3417)
30–49
HPV+ 60.3% (1024) 14.3% (243) 13.7% (233) 6.0% (102) 5.6% (95) 100% (1697)
HPV 92% (11 067) 6.4% (776) 1.4% (165) 0.17% (20) 0.05% (6) 100% (12 034)
50–64
HPV+ 83.6% (307) 6.8% (25) 4.9% (18) 2.4% (9) 2.2% (8) 100% (367)
HPV 94.7% (4968) 4.3% (223) 0.9% (47) 0.13% (7) 0.02% (1) 100% (5246)
20–64
HPV+ 58.4% (2226) 14.6% (557) 16.1% (613) 6.1% (233) 4.8% (184) 100% (3813)
HPV 92.5% (19 154) 5.9% (1232) 1.3% (265) 0.18% (38) 0.04% (8) 100% (20 697)
( ): number of women HPV positive (negative) in that category.
Table 3 Prevalence of HPV 16, HPV 18 and other high risk HPV types by age, cytology and histology at entry
Age HC-II negatives HPV 16 HPV 18 (not HPV 16) Other HC-II positivesa Total
20–24 1548 (60.1%) 315 (12.2%) 80 (3.1%) 632 (24.6%) 2575 (100%)
25–34 4867 (77.6%) 320 (5.1%) 127 (2.0%) 957 (15.3%) 6271 (100%)
25–34 6538 (89.2%) 112 (1.5%) 43 (0.6%) 638 (8.7%) 7331 (100%)
45–54 4707 (92.2%) 35 (0.7%) 15 (0.3%) 345 (6.8%) 5102 (100%)
55–64 3037 (94.0%) 21 (0.7%) 7 (0.2%) 166 (5.1%) 3231 (100%)
Cytology
Normal 19 154 (89.6%) 318 (1.5%) 143 (0.7%) 1765 (8.2%) 21 380 (100%)
Borderline 1232 (68.9%) 125 (7.0%) 54 (3.0%) 378 (21.1%) 1789 (100%)
Mild 265 (30.2%) 152 (17.3%) 40 (4.6%) 421 (47.9%) 878 (100%)
Moderate 38 (14.0%) 107 (39.5%) 18 (6.6%) 108 (39.9%) 271 (100%)
Severe or worse 8 (4.2%) 101 (52.6%) 17 (8.8%) 66 (34.4%) 192 (100%)
Histology
CIN1 or less 318 (40.8%) 104 (13.3%) 48 (6.2%) 310 (39.7%) 780 (100%)
CIN2 15 (7.1%) 85 (40.1%) 15 (7.1%) 97 (45.7%) 212 (100%)
CIN3/SCC 7 (2.7%) 157 (60.4%) 14 (5.4%) 82 (31.5%) 260 (100%)
CGIN/ADCC 3 (16.7%) 6 (33.3%) 6 (33.3%) 3 (16.7%) 18 (100%)
Abnormal cytology, no histology** 1200 (64.5%) 133 (7.1%) 46 (2.5%) 481 (25.9%) 1860 (100%)
Total 20 697 (84.4%) 803 (3.3%) 272 (1.1%) 2738 (11.2%) 24 510 (100%)
SCC: squamous cell carcinoma. CGIN: cervical glandular intraepithelial neoplasia. ADCC: adenocarcinoma. aNot HPV 16 or HPV 18. ** Women with abnormal cytology at entry
but no histology (abnormal cytology resolved or still being followed-up cytologically).
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cytology and hc2 testing, but our overall HPV prevalence was
slightly higher at each age. HPV prevalence in the HART study
declined from 14.5% in women aged 30–34 years to 3.8% in
women aged 55– 59 years (Cuzick et al, 2003); the corresponding
rates in our cohort were 18.5% at 30–34 years and 6% at 55– 59
years. Our higher rates may be partly due to regional differences in
the UK (2004). The HART study was conducted in five centres
across Britain, and the highest HPV prevalence was found in the
Manchester area, where 16% of 30– 34 year olds were positive for
HPV (P Sasieni, personal communication). There may also have
been a continuing increase in HPV prevalence in this population.
A study conducted in the same area as ARTISTIC between 1988
and 1993 reported HPV prevalence based on MY0911 consensus
primer PCR of 18% in women aged 20–24 years declining to 3% in
women aged 50–54 years (Peto et al, 2004). Differences in HPV
detection sensitivity may account for part of the disparity, but
this doubling of prevalence within 12 years suggests a continuing
epidemic rise in HPV prevalence.
Several useful conclusions relevant to the potential role for
HPV testing in primary routine screening are suggested by the
relationships between age, HPV detection and severity of cytology
shown. In women with detectable HPV the prevalence of moderate
dyskaryosis is 20- to 30-fold higher than in HPV negative women
at all ages, and severe dyskaryosis is increased more than 100-fold.
The prevalence of mild dyskaryosis in HPV-positive women is
about 10-fold higher than in HPV negative women below age 50
years and more than five-fold higher above age 50 years. Although
a great majority (87%) of women aged under 30 years with mild
dyskaryosis are HPV positive, this proportion falls to 58% (233/
398) at age 30 –49 years and to only 28% (18/65) at age 50– 64
years suggesting a role for HPV triage. The prevalence of
borderline abnormalities in HPV positive women is about twice
as high as in HPV-negative women at each age, and although there
may be some overcalling by LBC, our results indicate that many
borderline abnormalities are not caused by HPV. The prevalence
of moderate or severe dyskaryosis in HPV-positive women is
11.6% throughout the premenopausal years suggesting that the
natural history of HPV infection may be much the same in
premenopausal women irrespective of age, although CIN3 is rarer
in HPV-infected women aged 50 years or over. In women aged 30
years or over, our data suggest that the main effect of replacing
cytology by HPV testing in primary screening would be the
replacement of HPV negative abnormal smears, most of which
would be borderline, by a similar number of HPV positive normal
smears among women referred for follow-up. For those aged
20–29 years, however, the number who were HR HPV positive was
52% greater than the number with abnormal cytology, suggesting
the need for a secondary test prior to colposcopy.
Primary screening with HPV testing in combination with
cytology triage has been recommended only in women aged over
30 years (Sasieni and Cuzick, 2002; Cuzick et al, 2003), as HPV is
so common in younger women. This conclusion seems question-
able in the light of our results as high-grade dysplasia is as
common among HPV-infected women aged under 30 years as in
those age 30–49 years, and much commoner than in women aged
over 50 years.
The ARTISTIC trial has also provided the largest collection of
HPV typed primary screening cervical samples from the UK. The
HPV type may be clinically important as the proportion of hc2
positive women who were infected with HPV16 increased with
cytological abnormality, from 14% in those with normal cytology
to 55% in those with severe dyskaryosis (Table 3). The HPV type
might be used to determine whether to refer for colposcopy
immediately, repeat the test, or defer any investigation until the
next routine screen 3 years later. With the prospect of type 16/18
specific HPV prophylactic vaccines becoming available, data
on these types in the screened population is of considerable
importance in terms of what proportion of current abnormalities
may still occur, notwithstanding a degree of cross protection
reported for HPV 45 (Harper et al, 2006).
Women are still undergoing repeat cytology and colposcopy as
necessary. It is therefore not yet possible to compare the sensitivity
and specificity of cytology and HPV testing for detecting CIN2 and
CIN3 at entry to the trial, particularly in relation to specific HPV
types. As with any quantitative test, the performance of hc2 will
depend on the choice of cutoff.
The second round of screening at 3 years began in July 2004 and
we anticipate reporting final results at the end of 2007.
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